Polymyalgia Rheumatica - Pipeline Insight, 2025
Description
DelveInsight’s, Polymyalgia Rheumatica - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Polymyalgia Rheumatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polymyalgia Rheumatica: Overview
Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in white adults over 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) being the common findings. PMR patients can have coexisting and/or develop giant cell arteritis (GCA).
Polymyalgia rheumatica is an immune-mediated disorder, and elevated inflammatory markers are one of the most common features. IL-6 appears to have a central role in mediating inflammation.Interferon (IFN) may be present in temporal artery biopsy in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis. An elevated IgG4 level was found in patients with PMR but less frequently so in patients with GCA. The same study discovered an increased number of patients with PMR features and without elevation of IgG4 disease to have simultaneous GCA.
""Polymyalgia Rheumatica - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polymyalgia Rheumatica pipeline landscape is provided which includes the disease overview and Polymyalgia Rheumatica treatment guidelines. The assessment part of the report embraces, in depth Polymyalgia Rheumatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polymyalgia Rheumatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
SPI-62: Sparrow Pharmaceuticals
SPI-62 is our proprietary, oral small molecule, new chemical entity, HSD-1 inhibitor, designed to reduce intracellular cortisol levels and mitigate its numerous adverse effects. We are currently developing SPI-62 for conditions directly caused by an overproduction of cortisol in the body..
Further product details are provided in the report……..
Polymyalgia Rheumatica: Therapeutic Assessment
This segment of the report provides insights about the Polymyalgia Rheumatica drugs segregated based on following parameters that define the scope of the report, such as:
Polymyalgia Rheumatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polymyalgia Rheumatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polymyalgia Rheumatica drugs.
Polymyalgia Rheumatica Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Polymyalgia Rheumatica: Overview
Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in white adults over 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) being the common findings. PMR patients can have coexisting and/or develop giant cell arteritis (GCA).
Polymyalgia rheumatica is an immune-mediated disorder, and elevated inflammatory markers are one of the most common features. IL-6 appears to have a central role in mediating inflammation.Interferon (IFN) may be present in temporal artery biopsy in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis. An elevated IgG4 level was found in patients with PMR but less frequently so in patients with GCA. The same study discovered an increased number of patients with PMR features and without elevation of IgG4 disease to have simultaneous GCA.
""Polymyalgia Rheumatica - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polymyalgia Rheumatica pipeline landscape is provided which includes the disease overview and Polymyalgia Rheumatica treatment guidelines. The assessment part of the report embraces, in depth Polymyalgia Rheumatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polymyalgia Rheumatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Polymyalgia Rheumatica. The therapies under development are focused on novel approaches to treat/improve Polymyalgia Rheumatica.
SPI-62: Sparrow Pharmaceuticals
SPI-62 is our proprietary, oral small molecule, new chemical entity, HSD-1 inhibitor, designed to reduce intracellular cortisol levels and mitigate its numerous adverse effects. We are currently developing SPI-62 for conditions directly caused by an overproduction of cortisol in the body..
Further product details are provided in the report……..
Polymyalgia Rheumatica: Therapeutic Assessment
This segment of the report provides insights about the Polymyalgia Rheumatica drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Polymyalgia Rheumatica
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Polymyalgia Rheumatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polymyalgia Rheumatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polymyalgia Rheumatica drugs.
Polymyalgia Rheumatica Report Insights
- Polymyalgia Rheumatica Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Polymyalgia Rheumatica drugs?
- How many Polymyalgia Rheumatica drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polymyalgia Rheumatica?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polymyalgia Rheumatica therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polymyalgia Rheumatica and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bristol-Myers Squibb
- Eli Lilly and Company
- Chugai Pharmaceutical
- Sparrow Pharmaceuticals
- Abatacept
- Baricitinib
- Tocilizumab
- SPI 62
- SPI 47
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Polymyalgia Rheumatica: Overview
- What is Polymyalgia Rheumatica?
- Types of Polymyalgia Rheumatica
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Polymyalgia Rheumatica– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Abatacept: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Baricitinib: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SBP 101: Takeda Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SPI 62: Sparrow Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Polymyalgia Rheumatica Key Companies
- Polymyalgia Rheumatica Key Products
- Polymyalgia Rheumatica- Unmet Needs
- Polymyalgia Rheumatica- Market Drivers and Barriers
- Polymyalgia Rheumatica- Future Perspectives and Conclusion
- Polymyalgia Rheumatica Analyst Views
- Polymyalgia Rheumatica Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
